Genetic screening in early-onset Alzheimer's disease identified three novel presenilin mutations

Tsz Hang Wong, Harro Seelaar, Shamiram Melhem, Annemieke J. M. Rozemuller, John C. van Swieten

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)


Mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) are major genetic causes of early-onset Alzheimer's disease (EOAD). Clinical heterogeneity is frequently observed in patients with PSEN1 and PSEN2 mutations. Using whole exome sequencing, we screened a Dutch cohort of 68 patients with EOAD for rare variants in Mendelian Alzheimer's disease, frontotemporal dementia, and prion disease genes. We identified 3 PSEN1 and 2 PSEN2 variants. Three variants, 1 in PSEN1 (p.H21Profs*2) and both PSEN2 (p.A415S and p.M174I), were novel and absent in control exomes. These novel variants can be classified as probable pathogenic, except for PSEN1 (p.H21Profs*2) in which the pathogenicity is uncertain. The initial clinical symptoms between mutation carriers varied from behavioral problems to memory impairment. Our findings extend the mutation spectrum of EOAD and underline the clinical heterogeneity among PSEN1 and PSEN2 mutation carriers. Screening for Alzheimer's disease–causing genes is indicated in presenile dementia with an overlapping clinical diagnosis.
Original languageEnglish
Pages (from-to)201.e9-201.e14
JournalNeurobiology of aging
Early online date29 Jan 2019
Publication statusPublished - 1 Feb 2020


  • Early-onset Alzheimer's disease
  • Exome sequencing
  • PSEN1
  • PSEN2

Cite this